Remebroks - instructions for use, doses, side effects, contraindications

Excipients: propylene glycol 416.6 mg, methyl parahydroxybenzoate 10 mg, propyl parahydroxybenzoate 1 mg, disodium edetate 2.5 mg, citric acid monohydrate 2.50 mg, menthol 1 mg, black currant flavor 12.75 mg, crimson dye [Ponso 4R] - 0,083 mg, purified water -167 mg, sorbitol - up to 5 ml.

Description:

Transparent liquid, pink with a sweet taste and a fruity smell.

Pharmacotherapeutic group:Expectorant, mucolytic agent

ATX: & nbsp

R.05.C.B.06 Ambroxol

Pharmacodynamics:

Ambroxol (an active metabolite of bromhexine) possesses a secreto-motor, secretolitic and expectorant action; stimulates serous cells of the glands, bronchial mucosa, increases the content of mucous secretions and the release of surfactant (surfactant) in the alveoli and bronchi; normalizes the disturbed ratio of serous and mucous components of sputum. Activating hydrolyzing enzymes and enhancing the release of lysosomes from Clark cells, reduces the viscosity of phlegm. Increases the motor activity of cilia of ciliated epithelium, increases mucociliary transport of sputum. After oral administration, the therapeutic effect occurs after 30 minutes and persists for 6-12 hours (depending on the dose taken).

Pharmacokinetics:

Bioavailability of ambroxol is 70-80%. When ingested, the drug is almost completely absorbed from the gastrointestinal tract (GIT). Time to reach the maximum concentration in blood plasma - 2 h, connection with blood plasma proteins - 80%.

Penetrates through the blood-brain barrier, placental barrier, excreted in breast milk.Metabolized in the liver, forms dibromantranilic acid and glucuronic conjugates. The half-life (T1 / 2) is 7-12 hours. It is excreted by the kidneys: 90% in the form of water-soluble metabolites, in unchanged form - 5%. T1 / 2 increases with severe chronic renal failure, but does not change if the liver function is impaired.

Indications:Diseases of the respiratory tract with the release of viscous sputum: acute and chronic bronchitis, pneumonia, chronic obstructive pulmonary disease, bronchial asthma with difficulty of sputum discharge, bronchiectatic disease.

Contraindications:Hypersensitivity to ambroxol and / or other components of the drug, pregnancy (I trimester); children under 5 years of age, fructose intolerance and glucose / galactose absorption disorder or sucrose / isomaltase deficiency.

Carefully:Pregnancy (II - III trimester) and lactation period, renal and / or liver failure, peptic ulcer of stomach and duodenum.

Pregnancy and lactation:

The drug is not recommended for use during the first trimester of pregnancy. During pregnancy (II - III trimester), the use of the drug is possible only in those cases, when the intended use for the mother exceeds the potential risk to the fetus and / or the child. Because the drug penetrates into breast milk, during lactation to resolve the issue of stopping breastfeeding.

Dosing and Administration:

Remebroks syrup should be taken inside after eating, drinking plenty of fluid, which leads to increased mucolytic effect of the drug. Usually the following doses are used (5 ml of syrup contains 30 mg of ambroxol).

Adults and children over 12 years of age: it is recommended to take 5 ml (1 teaspoon) 2-3 times a day.

Children from 5 to 12 years old: it is recommended to take 2.5 ml (0.5 teaspoonful) 3 times a day. The duration of treatment depends on the features of the course of the disease.

Taking the drug for more than 4-5 days - only under the supervision of a doctor.

Side effects:Allergic reactions: skin rash, urticaria, angioedema, in some cases - allergic contact dermatitis, anaphylactic shock. Rarely: weakness,headache, rhinorrhea, increased salivation, dryness of the oral mucosa and the respiratory tract, exanthema, constipation, urination (dysuria).With prolonged use in high doses - gastralgia, nausea, vomiting.

Overdose:

Symptoms: nausea, vomiting, diarrhea, indigestion.

Treatment: artificial provocation of vomiting, gastric lavage in the first 1-2 hours after taking the drug; reception of fat-containing products; symptomatic therapy.

Interaction:Simultaneous use with antitussive drugs leads to difficulty in withdrawing sputum on the background of a reduction in cough. Simultaneous administration with amoxicillin, cefuroxime, erythromycin, doxycycline leads to an increase in the concentration of antibiotics in the lung tissue.

Special instructions:

The drug can be used in patients with diabetes, but it must be taken into account that the drug Remebroks contains sorbitol (5 ml of syrup contain sorbitol in an amount equivalent to 0.2 HeU).

Do not combine with antitussive drugs that hamper the excretion of phlegm. Patients taking Remebroks is not recommended. performance of respiratory gymnastics; In seriously ill patients, aspiration of diluted sputum should be performed.

In patients with bronchial asthma ambroxol can strengthen cough.

Do not take the drug Remebroks just before bedtime.

Effect on the ability to drive transp. cf. and fur:

The effect of the drug on the ability to drive vehicles and work with mechanisms that require an increased speed of psychomotor reactions has not been studied.

Form release / dosage:Syrup 30 mg / 5 ml.

Packaging:

For 100 ml or 200 ml in a bottle of brown glass. One bottle together with the instruction for use is placed in a cardboard box.

Storage conditions:

Store in a dry, dark place at a temperature of no higher than 25 ° C. Do not freeze.

Keep out of the reach of children.

Shelf life:3 years. Do not use after the expiration date stated on the package.

Terms of leave from pharmacies:Without recipe

Registration number:LP-000598

Date of registration:21.09.2011

The owner of the registration certificate:REMEDIYA, LLC REMEDIYA, LLC Russia

Manufacturer: & nbsp

REMEDIA THERAPEUTICS, Pvt. Ltd. India

Information update date: & nbsp23.09.2015

Illustrated instructions

Instructions

Remebroks (Remebrox)